Document Server@UHasselt >
Research publications >
Please use this identifier to cite or link to this item:
|Title: ||Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission|
|Authors: ||BUYSE, Marc|
Lucchesi, Kathryn J.
Brune, Mats L.
Rowe, Jacob M.
|Issue Date: ||2011|
|Publisher: ||FERRATA STORTI FOUNDATION|
|Citation: ||HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 96 (8). p. 1106-1112|
|Abstract: ||Background In trials designed to evaluate new therapies for hematologic malignancies, end points such as leukemia-free survival are often used as surrogates for overall survival in acute leukemia. We aimed to assess whether leukemia-free survival is an acceptable statistical surrogate for overall survival when applied to remission maintenance therapy for acute myeloid leukemia. Design and Methods Data were analyzed from a randomized Phase III trial of remission maintenance immunotherapy with histamine dihydrochloride plus low-dose interleukin-2 versus no treatment in adults with acute myeloid leukemia. A two-stage surrogate validation model was applied in which correlations between Kaplan-Meier estimates of leukemia-free survival and overall survival, and between log hazard ratios reflecting treatment effects were analyzed. Country of patient enrollment was the unit of analysis. Results Kaplan-Meier estimates of overall survival at 36, 48, and 60 months and leukemia-free survival at 24 months were reasonably correlated (R(2) ranging from 0.44 to 0.84) both for the overall (n=320) and first complete remission (n=261) populations. The effects of histamine dihydrochloride/interleukin-2 on log hazard ratios for leukemia-free survival and overall survival were well correlated (R(2)=0.88-0.93). Conclusions The significant correlations between overall survival and the surrogate end point (leukemia-free survival) and between the effect of histamine dihydrochloride/interleukin-2 on leukemia-free survival and overall survival satisfy the two-stage surrogate validation model. (ClinicalTrials.gov Identifier: NCT00003991)|
|Notes: ||[Buyse, M; Squifflet, P] IDDI, B-1340 Louvain, Belgium [Buyse, M] Hasselt Univ, Ctr Stat, I BioStat, Diepenbeek, Belgium [Michiels, S] Inst Jules Bordet, B-1000 Brussels, Belgium [Lucchesi, KJ] MedVal Sci Informat Serv LLC, Skillman, NJ USA [Hellstrand, K; Brune, ML] Univ Gothenburg, Sahlgrenska Acad, Gothenburg, Sweden [Castaigne, S] Hop Andre Mignot, Le Chesnay, France [Rowe, JM] Rambam Med Ctr, Haifa, Israel [Rowe, JM] Technion Israel Inst Technol, Haifa, Israel
|ISI #: ||000294722700007|
|Type: ||Journal Contribution|
|Validation: ||ecoom, 2012|
|Appears in Collections: ||Research publications|
Files in This Item:
|published version||405.73 kB||Adobe PDF|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.